disopyramide has been researched along with Hypoxia in 3 studies
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.
Hypoxia: Sub-optimal OXYGEN levels in the ambient air of living organisms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The hemodynamic and right ventricular volumetric effects of disopyramide were investigated in patients with tetralogy of Fallot (TF)." | 7.70 | Disopyramide improves hypoxia in patients with tetralogy of Fallot through a negative inotropic action. ( Chiba, S; Fuse, S; Hatakeyama, K; Higashidate, Y; Takamuro, M; Tomita, H, 1999) |
| "The hemodynamic and right ventricular volumetric effects of disopyramide were investigated in patients with tetralogy of Fallot (TF)." | 3.70 | Disopyramide improves hypoxia in patients with tetralogy of Fallot through a negative inotropic action. ( Chiba, S; Fuse, S; Hatakeyama, K; Higashidate, Y; Takamuro, M; Tomita, H, 1999) |
| "Amrubicin is a novel synthetic 9-aminoanthracycline derivative and is converted enzymatically to its C-13 hydroxy metabolite, amrubicinol, whose cytotoxic activity is 10-100 times that of amrubicin." | 2.72 | Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. ( Fujii, S; Hamada, A; Kishi, H; Matsunaga, Y; Mori, I; Okamoto, I; Saito, H; Sasaki, J; Semba, H; Uramoto, H; Yamagata, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okamoto, I | 1 |
| Hamada, A | 1 |
| Matsunaga, Y | 1 |
| Sasaki, J | 1 |
| Fujii, S | 1 |
| Uramoto, H | 1 |
| Yamagata, H | 1 |
| Mori, I | 1 |
| Kishi, H | 1 |
| Semba, H | 1 |
| Saito, H | 1 |
| Tomita, H | 1 |
| Fuse, S | 1 |
| Hatakeyama, K | 1 |
| Takamuro, M | 1 |
| Higashidate, Y | 1 |
| Chiba, S | 1 |
| Pacini, DJ | 1 |
| Boachie-Ansah, G | 1 |
| Kane, KA | 1 |
1 trial available for disopyramide and Hypoxia
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Agents; Area Under Curve; Atrial Fibrillation; Carcinoma, Non-S | 2006 |
2 other studies available for disopyramide and Hypoxia
| Article | Year |
|---|---|
Disopyramide improves hypoxia in patients with tetralogy of Fallot through a negative inotropic action.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Blood Pressure; Child; Child, Preschool; Disopyramide; Fe | 1999 |
Modification by hypoxia, hyperkalaemia and acidosis of the cardiac electrophysiological effects of a range of antiarrhythmic drugs.
Topics: Acidosis; Action Potentials; Animals; Anti-Arrhythmia Agents; Disopyramide; Electrocardiography; Ele | 1992 |